{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T23:14:06Z","timestamp":1793315646702,"version":"4.5.0"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T00:00:00Z","timestamp":1777939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T00:00:00Z","timestamp":1777939200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Pharmacologic targeting of murine double minute 2 (MDM2) represents one of the most compelling strategies for therapeutic reactivation of wild-type p53 in hematologic malignancies. The MDM2\u2013p53 autoregulatory loop is a central regulator of cellular stress responses, and in myeloid neoplasms\u2014including acute myeloid leukemia (AML) and myeloproliferative neoplasms (MPN)\u2014p53 is frequently retained but functionally suppressed through MDM2 overexpression and oncogenic signaling, notably via JAK\u2013STAT activation. Over the past decade, successive generations of MDM2 inhibitors have translated structural and mechanistic insights into clinical investigation, yielding critical lessons regarding dosing paradigms, hematologic toxicity, biomarker-driven patient selection, and mechanisms of resistance, including TP53-mutant clonal selection. While early phase III trials in AML were negative, recent studies in myelofibrosis demonstrate clinically meaningful spleen, symptom, and molecular responses, supporting disease-modifying potential in TP53\u2013wild-type settings. Adaptive platform designs and rational combinations with JAK inhibitors, BCL-2 antagonists, and interferons have further refined therapeutic strategies. Emerging MDM2 degraders and next-generation agents aim to overcome feedback limitations and improve therapeutic index. This review integrates mechanistic foundations, clinical development, resistance biology, and future directions, highlighting how decades of basic science have reshaped p53 reactivation into a precision therapeutic paradigm in myeloid disease.<\/jats:p>","DOI":"10.1038\/s41375-026-02975-6","type":"journal-article","created":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T06:46:01Z","timestamp":1777963561000},"page":"1111-1121","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["MDM2 inhibitors in myeloid cancers: from basic biology to clinical use in myeloproliferative neoplasms"],"prefix":"10.1038","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5009-2239","authenticated-orcid":false,"given":"Haifa K.","family":"Al-Ali","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah T.","family":"Heidel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8367-5668","authenticated-orcid":false,"given":"Francesca","family":"Palandri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2438-1955","authenticated-orcid":false,"given":"Florian H.","family":"Heidel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,5]]},"reference":[{"key":"2975_CR1","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1038\/nrc991","volume":"3","author":"P Chene","year":"2003","unstructured":"Chene P. Inhibiting the p53-MDM2 interaction: an important target for cancer therapy. Nat Rev Cancer. 2003;3:102\u20139.","journal-title":"Nat Rev Cancer"},{"key":"2975_CR2","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1126\/science.274.5289.948","volume":"274","author":"PH Kussie","year":"1996","unstructured":"Kussie PH, Gorina S, Marechal V, Elenbaas B, Moreau J, Levine AJ, et al. Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science. 1996;274:948\u201353.","journal-title":"Science"},{"key":"2975_CR3","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/S1535-6108(03)00134-X","volume":"3","author":"MA Lohrum","year":"2003","unstructured":"Lohrum MA, Ludwig RL, Kubbutat MH, Hanlon M, Vousden KH. Regulation of HDM2 activity by the ribosomal protein L11. Cancer Cell. 2003;3:577\u201387.","journal-title":"Cancer Cell"},{"key":"2975_CR4","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.molcel.2006.01.020","volume":"21","author":"CL Brooks","year":"2006","unstructured":"Brooks CL, Gu W. p53 ubiquitination: Mdm2 and beyond. Mol Cell. 2006;21:307\u201315.","journal-title":"Mol Cell"},{"key":"2975_CR5","first-page":"1","volume":"59","author":"DA Freedman","year":"1999","unstructured":"Freedman DA, Levine AJ. Regulation of the p53 protein by the MDM2 oncoprotein\u2013thirty-eighth G.H.A. Clowes Memorial Award Lecture. Cancer Res. 1999;59:1\u20137.","journal-title":"Cancer Res"},{"key":"2975_CR6","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1007\/s000180050273","volume":"55","author":"DA Freedman","year":"1999","unstructured":"Freedman DA, Wu L, Levine AJ. Functions of the MDM2 oncoprotein. Cell Mol Life Sci. 1999;55:96\u2013107.","journal-title":"Cell Mol Life Sci"},{"key":"2975_CR7","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1002\/(SICI)1096-9896(199901)187:1<112::AID-PATH250>3.0.CO;2-3","volume":"187","author":"C Prives","year":"1999","unstructured":"Prives C, Hall PA. The p53 pathway. J Pathol. 1999;187:112\u201326.","journal-title":"J Pathol"},{"key":"2975_CR8","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1101\/gad.7.7a.1126","volume":"7","author":"X Wu","year":"1993","unstructured":"Wu X, Bayle JH, Olson D, Levine AJ. The p53-mdm-2 autoregulatory feedback loop. Genes Dev. 1993;7:1126\u201332.","journal-title":"Genes Dev"},{"key":"2975_CR9","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.cell.2009.04.037","volume":"137","author":"KH Vousden","year":"2009","unstructured":"Vousden KH, Prives C. Blinded by the light: the growing complexity of p53. Cell. 2009;137:413\u201331.","journal-title":"Cell"},{"key":"2975_CR10","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1038\/sj.onc.1201432","volume":"15","author":"J Piette","year":"1997","unstructured":"Piette J, Neel H, Marechal V. Mdm2: keeping p53 under control. Oncogene. 1997;15:1001\u201310.","journal-title":"Oncogene"},{"key":"2975_CR11","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1158\/2159-8290.CD-14-0736","volume":"5","author":"M Kleppe","year":"2015","unstructured":"Kleppe M, Kwak M, Koppikar P, Riester M, Keller M, Bastian L, et al. JAK-STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response. Cancer Discov. 2015;5:316\u201331.","journal-title":"Cancer Discov"},{"key":"2975_CR12","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1038\/onc.2011.313","volume":"31","author":"M Nakatake","year":"2012","unstructured":"Nakatake M, Monte-Mor B, Debili N, Casadevall N, Ribrag V, Solary E, et al. JAK2(V617F) negatively regulates p53 stabilization by enhancing MDM2 via La expression in myeloproliferative neoplasms. Oncogene. 2012;31:1323\u201333.","journal-title":"Oncogene"},{"key":"2975_CR13","doi-asserted-by":"crossref","unstructured":"Perner F, Pahl HL, Zeiser R, Heidel FH. Malignant JAK-signaling: at the interface of inflammation and malignant transformation. Leukemia. 2025;39:1011\u201330.","DOI":"10.1038\/s41375-025-02569-8"},{"key":"2975_CR14","doi-asserted-by":"publisher","first-page":"2587","DOI":"10.1158\/0008-5472.CAN-12-2807","volume":"73","author":"C Tovar","year":"2013","unstructured":"Tovar C, Graves B, Packman K, Filipovic Z, Higgins B, Xia M, et al. MDM2 small-molecule antagonist RG7112 activates p53 signaling and regresses human tumors in preclinical cancer models. Cancer Res. 2013;73:2587\u201397.","journal-title":"Cancer Res"},{"key":"2975_CR15","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1021\/ml4000657","volume":"4","author":"B Vu","year":"2013","unstructured":"Vu B, Wovkulich P, Pizzolato G, Lovey A, Ding Q, Jiang N, et al. Discovery of RG7112: a small-molecule MDM2 inhibitor in clinical development. ACS Med Chem Lett. 2013;4:466\u20139.","journal-title":"ACS Med Chem Lett"},{"key":"2975_CR16","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1158\/1078-0432.CCR-15-0481","volume":"22","author":"M Andreeff","year":"2016","unstructured":"Andreeff M, Kelly KR, Yee K, Assouline S, Strair R, Popplewell L, et al. Results of the phase I trial of RG7112, a small-molecule MDM2 antagonist in leukemia. Clin Cancer Res. 2016;22:868\u201376.","journal-title":"Clin Cancer Res"},{"key":"2975_CR17","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1021\/ml400359z","volume":"5","author":"Z Zhang","year":"2014","unstructured":"Zhang Z, Chu XJ, Liu JJ, Ding Q, Zhang J, Bartkovitz D, et al. Discovery of potent and orally active p53-MDM2 inhibitors RO5353 and RO2468 for potential clinical development. ACS Med Chem Lett. 2014;5:124\u20137.","journal-title":"ACS Med Chem Lett"},{"key":"2975_CR18","doi-asserted-by":"publisher","first-page":"5979","DOI":"10.1021\/jm400487c","volume":"56","author":"Q Ding","year":"2013","unstructured":"Ding Q, Zhang Z, Liu JJ, Jiang N, Zhang J, Ross TM, et al. Discovery of RG7388, a potent and selective p53-MDM2 inhibitor in clinical development. J Med Chem. 2013;56:5979\u201383.","journal-title":"J Med Chem"},{"key":"2975_CR19","doi-asserted-by":"publisher","first-page":"3742","DOI":"10.1158\/1078-0432.CCR-14-0460","volume":"20","author":"B Higgins","year":"2014","unstructured":"Higgins B, Glenn K, Walz A, Tovar C, Filipovic Z, Hussain S, et al. Preclinical optimization of MDM2 antagonist scheduling for cancer treatment by using a model-based approach. Clin Cancer Res. 2014;20:3742\u201352.","journal-title":"Clin Cancer Res"},{"key":"2975_CR20","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1007\/s00280-018-3534-7","volume":"81","author":"S Blotner","year":"2018","unstructured":"Blotner S, Chen LC, Ferlini C, Zhi J. Phase 1 summary of plasma concentration-QTc analysis for idasanutlin, an MDM2 antagonist, in patients with advanced solid tumors and AML. Cancer Chemother Pharmacol. 2018;81:597\u2013607.","journal-title":"Cancer Chemother Pharmacol"},{"key":"2975_CR21","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1158\/1078-0432.CCR-21-1295","volume":"28","author":"EM Stein","year":"2022","unstructured":"Stein EM, DeAngelo DJ, Chromik J, Chatterjee M, Bauer S, Lin CC, et al. Results from a first-in-human phase I study of siremadlin (HDM201) in patients with advanced wild-type TP53 solid tumors and acute leukemia. Clin Cancer Res. 2022;28:870\u201381.","journal-title":"Clin Cancer Res"},{"key":"2975_CR22","doi-asserted-by":"publisher","unstructured":"Verstovsek S, Al-Ali HK, Mascarenhas J, Perkins A, Vannucchi AM, Mohan SR, et al. BOREAS: a global, phase III study of the MDM2 inhibitor navtemadlin (KRT-232) in relapsed\/refractory myelofibrosis. Future Oncol. 2022; https:\/\/doi.org\/10.2217\/fon-2022-0901. [Online ahead of print].","DOI":"10.2217\/fon-2022-0901"},{"key":"2975_CR23","doi-asserted-by":"publisher","first-page":"3098","DOI":"10.1182\/blood-2012-02-410712","volume":"120","author":"M Lu","year":"2012","unstructured":"Lu M, Wang X, Li Y, Tripodi J, Mosoyan G, Mascarenhas J, et al. Combination treatment in vitro with Nutlin, a small-molecule antagonist of MDM2, and pegylated interferon-alpha 2a specifically targets JAK2V617F-positive polycythemia vera cells. Blood. 2012;120:3098\u2013105.","journal-title":"Blood"},{"key":"2975_CR24","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1182\/blood.2018893545","volume":"134","author":"J Mascarenhas","year":"2019","unstructured":"Mascarenhas J, Lu M, Kosiorek H, Virtgaym E, Xia L, Sandy L, et al. Oral idasanutlin in patients with polycythemia vera. Blood. 2019;134:525\u201333.","journal-title":"Blood"},{"key":"2975_CR25","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1182\/blood-2013-11-536854","volume":"124","author":"M Lu","year":"2014","unstructured":"Lu M, Xia L, Li Y, Wang X, Hoffman R. The orally bioavailable MDM2 antagonist RG7112 and pegylated interferon alpha 2a target JAK2V617F-positive progenitor and stem cells. Blood. 2014;124:771\u20139.","journal-title":"Blood"},{"key":"2975_CR26","doi-asserted-by":"publisher","first-page":"4195","DOI":"10.1182\/bloodadvances.2025015860","volume":"9","author":"DM Ross","year":"2025","unstructured":"Ross DM, Heidel FH, Perkins AC, Reiter A, Crodel C, Riley C, et al. ADORE: an open platform study of ruxolitinib in combination with other novel therapies in patients with myelofibrosis. Blood Adv. 2025;9:4195\u2013205.","journal-title":"Blood Adv"},{"key":"2975_CR27","doi-asserted-by":"crossref","unstructured":"Mascarenhas J, Popov VM, Mohan S, Z\u00fcbeyde NO, Kiladijan JJ, Al-Ali H. Results from the randomized, multicenter, global phase 3 BOREAS study: navtemadlin versus best available therapy in JAK inhibitor relapsed\/refractory myelofibrosis. Blood (ASH Annual Meeting Abstracts). 2024;144.","DOI":"10.1182\/blood-2024-201642"},{"key":"2975_CR28","doi-asserted-by":"crossref","unstructured":"Mascarenhas JO, Bose P, Hou H-A, Homenda W, Ross D, Mohan SR, et al. Disease-modifying activity of navtemadlin correlates with clinical responses in a randomized, multicenter, global phase 3 study (BOREAS) in JAK-inhibitor relapsed\/refractory myelofibrosis. Blood (ASH Annual Meeting Abstracts). 2024;144.","DOI":"10.1182\/blood-2024-205937"},{"key":"2975_CR29","doi-asserted-by":"crossref","unstructured":"Vachani P, Lange A, Delgado RG, Al-Ali HK, Hern\u00e1ndez-Rivas JM, Kiladjian JJ, et al. Potential Disease-Modifying Activity of Navtemadlin (KRT-232), a First-in-Class MDM2 Inhibitor, Correlates with Clinical Benefits in Relapsed\/Refractory Myelofibrosis (MF). Blood (ASH Annual Meeting Abstracts). 2021;138.","DOI":"10.1182\/blood-2021-147543"},{"key":"2975_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-025-00823-x","volume":"9","author":"V Khanna","year":"2025","unstructured":"Khanna V, Eslami G, Reyes R, Diep R, Fernandez-Pol S, Stehr H, et al. MDM2 inhibition is associated with the emergence of TP53-altered clonal hematopoiesis. NPJ Precis Oncol. 2025;9:34.","journal-title":"NPJ Precis Oncol"},{"key":"2975_CR31","doi-asserted-by":"publisher","first-page":"2813","DOI":"10.1182\/bloodadvances.2021005867","volume":"6","author":"N Maslah","year":"2022","unstructured":"Maslah N, Verger E, Giraudier S, Chea M, Hoffman R, Mascarenhas J, et al. Single-cell analysis reveals selection of TP53-mutated clones after MDM2 inhibition. Blood Adv. 2022;6:2813\u201323.","journal-title":"Blood Adv"},{"key":"2975_CR32","doi-asserted-by":"publisher","first-page":"2488","DOI":"10.1182\/blood.2024028239","volume":"145","author":"B Allen","year":"2025","unstructured":"Allen B, Bottomly D, Kohnke T, Wang A, Lin HY, Johnson K, et al. A CEBPB\/IL-1beta\/TNF-alpha feedback loop drives drug resistance to venetoclax and MDM2 inhibitors in monocytic leukemia. Blood. 2025;145:2488\u2013506.","journal-title":"Blood"},{"key":"2975_CR33","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1182\/blood.2022016362","volume":"141","author":"NG Daver","year":"2023","unstructured":"Daver NG, Dail M, Garcia JS, Jonas BA, Yee KWL, Kelly KR, et al. Venetoclax and idasanutlin in relapsed\/refractory AML: a nonrandomized, open-label phase 1b trial. Blood. 2023;141:1265\u201376.","journal-title":"Blood"},{"key":"2975_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00871-1","volume":"13","author":"J Senapati","year":"2023","unstructured":"Senapati J, Muftuoglu M, Ishizawa J, Abbas HA, Loghavi S, Borthakur G, et al. A Phase I study of Milademetan (DS3032b) in combination with low dose cytarabine with or without venetoclax in acute myeloid leukemia: Clinical safety, efficacy, and correlative analysis. Blood Cancer J. 2023;13:101.","journal-title":"Blood Cancer J"},{"key":"2975_CR35","doi-asserted-by":"publisher","first-page":"3154","DOI":"10.1080\/10428194.2022.2116932","volume":"63","author":"Y Wei","year":"2022","unstructured":"Wei Y, Zheng H, Lockyer PP, Darbaniyan F, Li Z, Kanagal-Shamanna R, et al. MDM2 antagonist improves therapeutic activity of azacitidine in myelodysplastic syndromes and chronic myelomonocytic leukemia. Leuk Lymphoma. 2022;63:3154\u201364.","journal-title":"Leuk Lymphoma"},{"key":"2975_CR36","doi-asserted-by":"publisher","first-page":"2574","DOI":"10.1182\/blood.2025028935","volume":"146","author":"BZ Carter","year":"2025","unstructured":"Carter BZ, Mak PY, Ayoub E, Wu X, Ke B, Nishida Y, et al. Restoring p53 wild-type conformation in TP53-Y220C-mutant acute myeloid leukemia. Blood. 2025;146:2574\u201388.","journal-title":"Blood"},{"key":"2975_CR37","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1186\/s13046-024-03220-7","volume":"43","author":"J Liu","year":"2024","unstructured":"Liu J, Wei L, Miao Q, Zhan S, Chen P, Liu W, et al. MDM2 drives resistance to Osimertinib by contextually disrupting FBW7-mediated destruction of MCL-1 protein in EGFR mutant NSCLC. J Exp Clin Cancer Res. 2024;43:302.","journal-title":"J Exp Clin Cancer Res"},{"key":"2975_CR38","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1080\/14796694.2026.2638989","volume":"22","author":"P Vachhani","year":"2026","unstructured":"Vachhani P, Yacoub A, Rampal R, Bradley T, Harrison C, Jain T, et al. POIESIS: a phase III study of add-on navtemadlin in JAK inhibitor-naive myelofibrosis patients with a suboptimal response to ruxolitinib. Future Oncol. 2026;22:781\u201393.","journal-title":"Future Oncol"},{"key":"2975_CR39","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1007\/s00280-015-2830-8","volume":"76","author":"A Patnaik","year":"2015","unstructured":"Patnaik A, Tolcher A, Beeram M, Nemunaitis J, Weiss GJ, Bhalla K, et al. Clinical pharmacology characterization of RG7112, an MDM2 antagonist, in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2015;76:587\u201395.","journal-title":"Cancer Chemother Pharmacol"},{"key":"2975_CR40","doi-asserted-by":"publisher","first-page":"267","DOI":"10.2147\/OTT.S440979","volume":"17","author":"N Yamamoto","year":"2024","unstructured":"Yamamoto N, Tolcher A, Hafez N, Lugowska I, Ramlau R, Macarulla T, et al. Efficacy and safety of the MDM2-p53 antagonist brigimadlin (BI 907828) in patients with advanced biliary tract cancer: a case series. Onco Targets Ther. 2024;17:267\u201380.","journal-title":"Onco Targets Ther"},{"key":"2975_CR41","doi-asserted-by":"publisher","first-page":"419","DOI":"10.4161\/cc.3.4.801","volume":"3","author":"LT Vassilev","year":"2004","unstructured":"Vassilev LT. Small-molecule antagonists of p53-MDM2 binding: research tools and potential therapeutics. Cell Cycle. 2004;3:419\u201321.","journal-title":"Cell Cycle"},{"key":"2975_CR42","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1126\/science.1092472","volume":"303","author":"LT Vassilev","year":"2004","unstructured":"Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z, et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science. 2004;303:844\u20138.","journal-title":"Science"},{"key":"2975_CR43","doi-asserted-by":"crossref","unstructured":"Clevenger T, Cheung J, Krantz F, Gulrajani M, Nguyen C, Luarca M, et al. Adding Navtemadlin (Nvtm) to Ruxolitinib (Rux) Potentiates Apoptosis in Myeloblasts from Patients (Pts) with Myelofibrosis (MF). Hemasphere (EHA Annual Meeting Abstracts). 2023;7.","DOI":"10.1097\/01.HS9.0000970868.28141.7f"},{"key":"2975_CR44","doi-asserted-by":"crossref","unstructured":"Mascarenhas J, Jain T, Otoukesh S, Gerds AT, Lucchesi A, Sosa IR, et al. AN OPEN-LABEL, GLOBAL, PHASE (PH) 1B\/2 STUDY ADDING NAVTEMADLIN (NVTM) TO RUXOLITINIB (RUX) IN PATIENTS (PTS) WITH PRIMARY OR SECONDARY MYELOFIBROSIS (MF) WHO HAVE A SUBOPTIMAL RESPONSE TO RUX. Hemasphere (EHA Annual Meeting Abstracts). 2023;7.","DOI":"10.1097\/01.HS9.0000967752.72578.ff"},{"key":"2975_CR45","doi-asserted-by":"crossref","unstructured":"Vachhani P, Yacoub A, Rampal R, Bradley T, Harrison C, Jain T, et al. POIESIS: a phase III study of add-on navtemadlin in JAKinhibitor-na\u00efve myelofibrosis patients with a suboptimal response to ruxolitinib. Future Oncol. 2026;22:781\u201393.","DOI":"10.1080\/14796694.2026.2638989"},{"key":"2975_CR46","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1158\/1541-7786.MCR-22-0898","volume":"21","author":"M Langenbach","year":"2023","unstructured":"Langenbach M, Giesler S, Richtsfeld S, Costa-Pereira S, Rindlisbacher L, Wertheimer T, et al. MDM2 inhibition enhances immune checkpoint inhibitor efficacy by increasing IL15 and MHC class II production. Mol Cancer Res. 2023;21:849\u201364.","journal-title":"Mol Cancer Res"},{"key":"2975_CR47","doi-asserted-by":"publisher","first-page":"9559","DOI":"10.1200\/JCO.2023.41.16_suppl.9559","volume":"41","author":"MF Shaheen","year":"2023","unstructured":"Shaheen MF, Segar JM, Chmielowski B, Drabick JJ, McKean M, Reeves JA, et al. A phase 2 study of alrizomadlin (APG-115) in combination with pembrolizumab in patients with unresectable or metastatic cutaneous melanoma that has failed immuno-oncologic (IO) drugs. J Clin Oncol. 2023;41:9559.","journal-title":"J Clin Oncol"},{"key":"2975_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.gendis.2024.101279","volume":"11","author":"Q Zeng","year":"2024","unstructured":"Zeng Q, Zeng S, Dai X, Ding Y, Huang C, Ruan R, et al. MDM2 inhibitors in cancer immunotherapy: current status and perspective. Genes Dis. 2024;11:101279.","journal-title":"Genes Dis"},{"key":"2975_CR49","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-89506-8","volume":"11","author":"Y Hirata","year":"2021","unstructured":"Hirata Y, Takahashi M, Yamada Y, Matsui R, Inoue A, Ashida R, et al. trans-Fatty acids promote p53-dependent apoptosis triggered by cisplatin-induced DNA interstrand crosslinks via the Nox-RIP1-ASK1-MAPK pathway. Sci Rep. 2021;11:10350.","journal-title":"Sci Rep"},{"key":"2975_CR50","doi-asserted-by":"publisher","first-page":"3421","DOI":"10.1007\/s00262-021-02940-5","volume":"70","author":"M Kono","year":"2021","unstructured":"Kono M, Kumai T, Hayashi R, Yamaki H, Komatsuda H, Wakisaka R, et al. Interruption of MDM2 signaling augments MDM2-targeted T cell-based antitumor immunotherapy through antigen-presenting machinery. Cancer Immunol Immunother. 2021;70:3421\u201334.","journal-title":"Cancer Immunol Immunother"},{"key":"2975_CR51","doi-asserted-by":"publisher","first-page":"5236","DOI":"10.1158\/1078-0432.CCR-21-0715","volume":"27","author":"MN Saleh","year":"2021","unstructured":"Saleh MN, Patel MR, Bauer TM, Goel S, Falchook GS, Shapiro GI, et al. Phase 1 Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type TP53. Clin Cancer Res. 2021;27:5236\u201347.","journal-title":"Clin Cancer Res"},{"key":"2975_CR52","doi-asserted-by":"crossref","unstructured":"Russano F, Sturlese M, Dall\u2019Olmo L, Callegarin F, Brugnolo D, Del Fiore P, et al. MDM2 in tumor biology and cancer therapy: a review of current clinical trials. Int J Mol Sci. 2025;27:99.","DOI":"10.3390\/ijms27010099"},{"key":"2975_CR53","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1038\/s41375-022-01735-6","volume":"37","author":"BK Marcellino","year":"2023","unstructured":"Marcellino BK, Yang X, Umit Kaniskan H, Brady C, Chen H, Chen K, et al. An MDM2 degrader for treatment of acute leukemias. Leukemia. 2023;37:370\u20138.","journal-title":"Leukemia"},{"key":"2975_CR54","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1158\/1535-7163.MCT-24-0306","volume":"24","author":"YK Chutake","year":"2025","unstructured":"Chutake YK, Mayo MF, Dumont N, Filiatrault J, Breitkopf SB, Cho P, et al. KT-253, a novel MDM2 degrader and p53 stabilizer, has superior potency and efficacy than MDM2 small-molecule inhibitors. Mol Cancer Ther. 2025;24:497\u2013510.","journal-title":"Mol Cancer Ther"},{"key":"2975_CR55","first-page":"4147","volume":"6","author":"MY Konopleva","year":"2022","unstructured":"Konopleva MY, Rollig C, Cavenagh J, Deeren D, Girshova L, Krauter J, et al. Idasanutlin plus cytarabine in relapsed or refractory acute myeloid leukemia: results of the MIRROS trial. Blood Adv. 2022;6:4147\u201356.","journal-title":"Blood Adv"},{"key":"2975_CR56","doi-asserted-by":"publisher","first-page":"807","DOI":"10.2217\/fon-2020-0044","volume":"16","author":"P Montesinos","year":"2020","unstructured":"Montesinos P, Beckermann BM, Catalani O, Esteve J, Gamel K, Konopleva MY, et al. MIRROS: a randomized, placebo-controlled, Phase III trial of cytarabine +\/- idasanutlin in relapsed or refractory acute myeloid leukemia. Future Oncol. 2020;16:807\u201315.","journal-title":"Future Oncol"},{"key":"2975_CR57","doi-asserted-by":"crossref","unstructured":"Kadia TM, Benton C, Erba HP, Gandhi M, Levy MY, Percival MEM, et al. Trial in Progress: Phase 1b\/2 Study of Alrizomadlin (APG-115), Alone or Combined with 5-Azacitidine (AZA), in Patients with Relapsed\/Refractory Acute Myeloid Leukemia (AML), Chronic Myelomonocytic Leukemia (CMML), or Myelodysplastic Syndrome (MDS). Blood (ASH Annual Meeting Abstracts). 2022 11659\u201360.","DOI":"10.1182\/blood-2022-162627"},{"key":"2975_CR58","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.1182\/bloodadvances.2019030916","volume":"3","author":"HP Erba","year":"2019","unstructured":"Erba HP, Becker PS, Shami PJ, Grunwald MR, Flesher DL, Zhu M, et al. Phase 1b study of the MDM2 inhibitor AMG 232 with or without trametinib in relapsed\/refractory acute myeloid leukemia. Blood Adv. 2019;3:1939\u201349.","journal-title":"Blood Adv"},{"key":"2975_CR59","first-page":"3984","volume":"42","author":"MR Kawaja","year":"2024","unstructured":"Kawaja MR, Naqash AR, Schneider R, Shastri A, Stahl M, Moser JC, et al. Safety, pharmacokinetics (PK), pharmacodynamics (PD) and efficacy of KT-253, a targeted protein degrader of MDM2, in patients with relapsed\/refractory (R\/R) solid tumors, lymphoma, high grade myeloid malignancies and acute lymphoblastic leukemia (ALL). J Clin Oncol. 2024;42:3984.","journal-title":"J Clin Oncol"},{"key":"2975_CR60","first-page":"3588","volume":"144","author":"M Lu","year":"2024","unstructured":"Lu M, Xia L, Chutake YK, Dey J, Hoffmann R. KT-253, a highly potent and selective MDM2 protein degrader, eliminates malignant myelofibrosis stem\/progenitor cells. Blood (ASH Annu Meet Abstr). 2024;144:3588.","journal-title":"Blood (ASH Annu Meet Abstr)"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-02975-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-02975-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-02975-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T07:02:41Z","timestamp":1780470161000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-02975-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,5]]},"references-count":60,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["2975"],"URL":"https:\/\/doi.org\/10.1038\/s41375-026-02975-6","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,5]]},"assertion":[{"value":"14 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"HAA: consulting or advisory role for BMS, Novartis, AbbVie, AOP Pharma, Blueprint, GSK, Otsuka, Stemline, MSD, Takeda; research funding from BMS, Incyte, Novartis; and travel support from Alexion and Abbvie. STH: none. FP: Consultancy and honoraria from NOVARTIS, GSK, BMS, INCYTE, SANOFI, TAKEDA, SOBI, AOP. FHH: honoraria from Novartis, Abbvie, CTI, BMS, MSD, GSK, AOP, Prelude, Silence, Telios, Kartos; consulting\/advisory role for Novartis, Abbvie, CTI, BMS, MSD, GSK, AOP, Prelude, Silence, Telios, Kartos, Sumitomo, Janssen; and research funding from Novartis, BMS, CTI.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}